Market Place
Sourcing Support
Ironwood to Participate in Jefferies London Health Conference
13 Nov 2024 //
BUSINESSWIRE
Ironwood Pharma Reports Q3 2024 Results
07 Nov 2024 //
BUSINESSWIRE
Ironwood makes bid for $1B GI drug with subgroup data
29 Oct 2024 //
FIERCE BIOTECH
Ironwood Pharmaceuticals To Host Q3 2024 Update Call
24 Oct 2024 //
BUSINESSWIRE
Ironwood To Attend Wells Fargo Healthcare Conference
29 Aug 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Second Quarter 2024 Results
08 Aug 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host Second Quarter 2024 Investor Update Call
25 Jul 2024 //
BUSINESSWIRE
Ironwood At Jefferies Global Healthcare Conference
30 May 2024 //
BUSINESSWIRE
Ironwood Presents Apraglutide SBS-IF Data At DDW Late-Breaker
21 May 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports First Quarter 2024 Results
09 May 2024 //
BUSINESSWIRE
Ironwood to Participate in The Citizens JMP Life Sciences Conference
06 May 2024 //
BUSINESSWIRE
Ironwood: Apraglutide SBS-IF Data At DDW 2024
01 May 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host First Quarter 2024 Investor Update Call
25 Apr 2024 //
BUSINESSWIRE
Ironwood spies new frontier for $1B drug in exploratory trial
29 Mar 2024 //
FIERCE BIOTECH
Ironwood Results from Ph II Trial of Apraglutide in Patients with SR GI aGVHD
28 Mar 2024 //
BUSINESSWIRE
Ironwood`s bowel disease drug meets main goal of late-stage study
01 Mar 2024 //
REUTERS
Ironwood Announces Positive Results from Phase III of Once-Weekly Apraglutide
29 Feb 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Present Four Abstracts at the ASPEN
23 Feb 2024 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Results
15 Feb 2024 //
BUSINESSWIRE
Ironwood to Host Fourth Quarter and Full Year 2023 Investor Update Call
01 Feb 2024 //
BUSINESSWIRE
Ironwood Announces Publication of Linaclotide Phase III Data
08 Jan 2024 //
BUSINESSWIRE
Ironwood to Present at the 42nd Annual J.P. Morgan Healthcare Conference
03 Jan 2024 //
BUSINESSWIRE
Ironwood Announces the Completion of Squeeze-Out Merger With VectivBio
12 Dec 2023 //
BUSINESSWIRE
Ironwood to Participate in the Piper Sandler 35th Annual Healthcare Conference
21 Nov 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Third Quarter 2023 Results
09 Nov 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host Third Quarter 2023 Investor Update Call
26 Oct 2023 //
BUSINESSWIRE
Ironwood Releases New IBS-C and CIC Data at Scientific Meeting
23 Oct 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Presents Positive Final Data from STARS Nutrition
16 Oct 2023 //
BUSINESSWIRE
Ironwood to Present New Data at NASPGHAN Annual Meeting
05 Oct 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Second Quarter 2023 Results
08 Aug 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host Second Quarter 2023 Investor Update Call
25 Jul 2023 //
BUSINESSWIRE
Ironwood & VectivBio Announce the Completion Tender Offer for VectivBio Shares
29 Jun 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Announces FDA Approval of New Indication for LINZESS
12 Jun 2023 //
BUSINESSWIRE
Ironwood pays $1B for VectivBio and its phase 3 GI drug
23 May 2023 //
FIERCE BIOTECH
Ironwood Enters into Definitive Agreement to Acquire VectivBio
22 May 2023 //
PRESS RELEASE
Ironwood Pharma to Participate in The JMP Securities Life Sciences Conference
09 May 2023 //
BUSINESSWIRE
Ironwood Presents New Data on Potential Linaclotide for Functional in Children
08 May 2023 //
BUSINESSWIRE
Ironwood to Present New Data at Digestive Disease Week® 2023 of Linaclotide
24 Apr 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host First Quarter 2023 Investor Update Call
20 Apr 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Participate in Upcoming Investor Conferences
27 Feb 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results
16 Feb 2023 //
BUSINESSWIRE
Ironwood Announces Priority Review of Supplemental NDA for LINZESS
13 Feb 2023 //
BUSINESSWIRE
Ironwood Pharma to Host Fourth Quarter and Full Year 2022 Investor Update Call
02 Feb 2023 //
BUSINESSWIRE
Ironwood Pharmaceuticals Provides Update on FY 2022 Financial Guidance
09 Jan 2023 //
BUSINESSWIRE
Ironwood to Present at the 41st Annual J.P. Morgan Healthcare Conference
04 Jan 2023 //
BUSINESSWIRE
Ironwood to Participate in the Piper Sandler 34th Annual Healthcare Conference
22 Nov 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results
03 Nov 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
20 Oct 2022 //
BUSINESSWIRE
Ironwood`s former pipeline spinout hits another speed bump
06 Oct 2022 //
ENPTS
Ironwood Pharma Reports Positive Topline Data from Phase III Trial of LINZESS
06 Sep 2022 //
BUSINESSWIRE
Ironwood Pharma to Present at the 2022 Wells Fargo Healthcare Conference
01 Sep 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; & more
04 Aug 2022 //
BUSINESSWIRE
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain
25 May 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data
09 May 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals Reports First Quarter 2022 Results
05 May 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals initiated at overweight at Piper on cash flow
22 Apr 2022 //
SEEKINGALPHA
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
21 Apr 2022 //
BUSINESSWIRE
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
02 Mar 2022 //
BUSINESSWIRE
Ironwood Reports Q4, Full Year 2021 Results; LINZESS Achieves Blockbuster Status
17 Feb 2022 //
BUSINESSWIRE
Ironwood Pharma Provides Update on FY 2021, Announces FY 2022 Financial Guidance
10 Jan 2022 //
BUSINESSWIRE
